Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Clinical trial NCT01371630 · RECRUITING

Trial details

NCT number: NCT01371630
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Burkitt-Like Lymphoma With 11q Aberration High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent B Acute Lymphoblastic Leukemia Recurrent Burkitt Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory Burkitt Lymphoma

Start date: 2011-08-26
Primary completion: 2027-12-25
Enrollment: 276

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.